Hikma Pharmaceuticals (OTCMKTS:HKMPF) Hits New 1-Year Low - Time to Sell?

Key Points

• Hikma Pharmaceuticals Plc reached a new 52-week low of $21.87 during trading, indicating a significant drop in its stock price.
• The company's current ratio is 1.24, with a debt-to-equity ratio of 0.33, reflecting its financial stability amid declining stock performance.
• Hikma operates through three segments: Injectables, Generics, and Branded, focusing on various pharmaceutical products, including generic injectables for hospitals.

Hikma Pharmaceuticals Plc (OTCMKTS:HKMPF - )'s share price hit a new 52-week low during mid-day trading on Thursday . The stock traded as low as $21.87 and last traded at $21.87, with a volume of 985 shares. The stock had previously closed at $22.09.

Hikma Pharmaceuticals Trading Down 1.0%

The company has a current ratio of 1.24, a quick ratio of 0.72 and a debt-to-equity ratio of 0.33. The company's fifty day simple moving average is $24.80 and its 200-day simple moving average is $26.23.

About Hikma Pharmaceuticals

Hikma Pharmaceuticals PLC develops, manufactures, markets, and sells a range of generic, branded, and in-licensed pharmaceutical products. It operates through three segments: Injectables, Generics, and Branded. The Injectables segment provides generic injectable products primarily for use in hospitals.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.